Naeem Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Naeem Khan has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Anna Ettorre
Oxford Biomedica (UK) Limited, Oxford, United Kingdom
14 shared publications - Bernard Souberbielle
Oxford Biomedica (UK) Limited, Oxford, United Kingdom
14 shared publications - Daniel G. Blount
Oxford Biomedica (UK) Limited, Oxford, United Kingdom
14 shared publications - Deirdre O’COnnor
Oxford Biomedica (UK) Limited, Oxford, United Kingdom
14 shared publications - Jenny Down
Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom
14 shared publications - Kyriacos Mitrophanous
Oxford Biomedica (UK) Limited, United Kingdom
14 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 1A. Gating Strategy for the analysis of AML samples. Supplementary Figure 1B. 5T4 surface expression in selected AML patient samples using Multi-parameter Flow Cytometry.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 1A. Gating Strategy for the analysis of AML samples. Supplementary Figure 1B. 5T4 surface expression in selected AML patient samples using Multi-parameter Flow Cytometry.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Table 2: 5T4 Expression in AML Cell Lines
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Table 2: 5T4 Expression in AML Cell Lines
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 2. Schematic representation and sequence of 5T4 construct
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 2. Schematic representation and sequence of 5T4 construct
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 3. Expression of 5T4 on Kasumi-1 cells and on the putative leukaemic stem cell population within Kasumi-1 cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 3. Expression of 5T4 on Kasumi-1 cells and on the putative leukaemic stem cell population within Kasumi-1 cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Table 1A. Disease information on 5T4+ AML samples ranked by rMFI (all >1.5). Supplementary Table 1B. 5T4+ AML samples ranked by MFC % (all >20%).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Table 1A. Disease information on 5T4+ AML samples ranked by rMFI (all >1.5). Supplementary Table 1B. 5T4+ AML samples ranked by MFC % (all >20%).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 4: 5T4 expression in normal tissues (Materials and Methods).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 4: 5T4 expression in normal tissues (Materials and Methods).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Chimeric antigen receptor (CAR) T cells represent a novel targeted approach to overcome deficits in the ability of the host immune system to detect and subsequently eradicate tumors. The identification of antigens expressed specifically on the surface of tumor cells is a critical first step for a targeted therapy that selectively targets cancer cells without affecting normal tissues. 5T4 is a tumor-associated antigen expressed on the cell surface of most solid tumors. However, very little is known about its expression in hematologic malignancies. In this study, we assess the expression of 5T4 in different types of leukemias, specifically acute myeloid leukemia (AML), and normal hematopoietic stem cells (HSC). We also provide an in vitro assessment of safety and efficacy of 5T4-targeting CAR T cells against HSCs and AML tumor cell lines. 5T4 expression was seen in about 50% of AML cases; AML with mutated nucleophosmin 1, AML–myelodysplasia-related, and AML not otherwise specified showed the highest percentage of 5T4+ cases. 5T4 CAR T cells efficiently and specifically killed AML tumor cell lines, including leukemic stem cells. Coculture of 5T4 CAR T cells with HSCs from healthy donors showed no impact on subsequent colony formation, thus confirming the safety profile of 5T4. A proof-of-concept study using a murine model for AML demonstrated that CAR T cells recognize 5T4 expressed on cells and can kill tumor cells both in vitro and in vivo. These results highlight 5T4 as a promising target for immune intervention in AML and that CAR T cells can be considered a powerful personalized therapeutic approach to treat AML.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Chimeric antigen receptor (CAR) T cells represent a novel targeted approach to overcome deficits in the ability of the host immune system to detect and subsequently eradicate tumors. The identification of antigens expressed specifically on the surface of tumor cells is a critical first step for a targeted therapy that selectively targets cancer cells without affecting normal tissues. 5T4 is a tumor-associated antigen expressed on the cell surface of most solid tumors. However, very little is known about its expression in hematologic malignancies. In this study, we assess the expression of 5T4 in different types of leukemias, specifically acute myeloid leukemia (AML), and normal hematopoietic stem cells (HSC). We also provide an in vitro assessment of safety and efficacy of 5T4-targeting CAR T cells against HSCs and AML tumor cell lines. 5T4 expression was seen in about 50% of AML cases; AML with mutated nucleophosmin 1, AML–myelodysplasia-related, and AML not otherwise specified showed the highest percentage of 5T4+ cases. 5T4 CAR T cells efficiently and specifically killed AML tumor cell lines, including leukemic stem cells. Coculture of 5T4 CAR T cells with HSCs from healthy donors showed no impact on subsequent colony formation, thus confirming the safety profile of 5T4. A proof-of-concept study using a murine model for AML demonstrated that CAR T cells recognize 5T4 expressed on cells and can kill tumor cells both in vitro and in vivo. These results highlight 5T4 as a promising target for immune intervention in AML and that CAR T cells can be considered a powerful personalized therapeutic approach to treat AML.
- Open Access
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 1A. Gating Strategy for the analysis of AML samples. Supplementary Figure 1B. 5T4 surface expression in selected AML patient samples using Multi-parameter Flow Cytometry.
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 1A. Gating Strategy for the analysis of AML samples. Supplementary Figure 1B. 5T4 surface expression in selected AML patient samples using Multi-parameter Flow Cytometry.
- Open Access
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 4: 5T4 expression in normal tissues (Materials and Methods).
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 4: 5T4 expression in normal tissues (Materials and Methods).
- Open Access
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 3. Expression of 5T4 on Kasumi-1 cells and on the putative leukaemic stem cell population within Kasumi-1 cells
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia
Supplementary Figure 3. Expression of 5T4 on Kasumi-1 cells and on the putative leukaemic stem cell population within Kasumi-1 cells